3 Risky Pot Stocks With Jaw-Dropping Growth Potential

Despite the legal marijuana industry growing at a blistering pace the past few years, cannabis stocks have generally been a downer for investors. Cannabis equities have floundered over the prior three years for a laundry list of reasons. Some of the common threads running through this…

disappointing period in the industry’s life cycle include: overzealous management teams, a sea of never-ending capital raises at shareholders’ expense, governmental red tape, banking/financing problems, the slow march toward federal legalization in the U.S., and of course, competition from both legal and illegal growers. As a result of this vortex of hurricane-force headwinds, the industry’s bellwether ETF — Horizons Marijuana Life Sciences Index ETF — has lost over 56% of its value over the prior 36-month period.

There is no doubting the industry’s overall growth potential, however. The global legal cannabis market is forecast to rake in $70.6 billion in sales by 2028, according to a report by Grand View Research. Legal marijuana sales, in effect, are expected to rise at a compound annual growth rate of 26.7% over the next seven years. If this forecast rings true, marijuana would easily be one of the fastest-growing industries in the world over this period.

How can marijuana investors capitalize on this parabolic growth trend? There are two emerging trends that investors should consider when buying marijuana stocks right now. Within the top end of the field from a market cap perspective, investors should arguably prize a company’s ability to simply stay in the game until the U.S. permits countrywide THC sales. Second, customers are reportedly shifting their tastes toward higher-quality dried flowers produced by elite craft growers. Armed with these insights, Canopy Growth (NYSEMKT:CGC)OrganiGram (NASDAQ:OGI), and Sundial Growers (NASDAQ:SNDL) are three names that could be big winners for patient investors. Here’s why.

Canopy, OrganiGram, and Sundial stand out from the crowd

Canopy Growth is Canada’s top seller of premium dried flower, according to data from the cannabis research firm Hifyre. What’s more, Canopy recently announced that its vape and edible products are also performing well in the marketplace. Even so, Canopy’s stock has dropped by over 44% so far this year. Investors have exited this pot stock this year in response to the company’s inability to turn a profit, as well as its hefty cash burn rate. The shift toward ultra-high-quality craft products and the company’s decision to place a heavy emphasis on the largely forbidden U.S. market have hurt its top line in 2021.

Canopy’s saving grace, though, is undoubtedly its partnership with U.S. liquor titan Constellation Brands. This partnership should give the company the runway necessary to wait out most of its would-be competitors, and potentially grab an outsize portion of the U.S. market upon federal permissibility. The big picture is that…

 

Continue reading at THE MOTLEY FOOL

 

Leave a Reply

Your email address will not be published. Required fields are marked *